AU2017270598B2 - Processes for preparing phosphorodiamidate morpholino oligomers - Google Patents

Processes for preparing phosphorodiamidate morpholino oligomers Download PDF

Info

Publication number
AU2017270598B2
AU2017270598B2 AU2017270598A AU2017270598A AU2017270598B2 AU 2017270598 B2 AU2017270598 B2 AU 2017270598B2 AU 2017270598 A AU2017270598 A AU 2017270598A AU 2017270598 A AU2017270598 A AU 2017270598A AU 2017270598 B2 AU2017270598 B2 AU 2017270598B2
Authority
AU
Australia
Prior art keywords
formula
dpg
compound
dcc
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017270598A
Other languages
English (en)
Other versions
AU2017270598A1 (en
Inventor
Bao Cai
Mitchell MARTINI
Ross SHIMABUKU
Katie THOMAS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sarepta Therapeutics Inc
Original Assignee
Sarepta Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sarepta Therapeutics Inc filed Critical Sarepta Therapeutics Inc
Publication of AU2017270598A1 publication Critical patent/AU2017270598A1/en
Application granted granted Critical
Publication of AU2017270598B2 publication Critical patent/AU2017270598B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polyethers (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2017270598A 2016-05-24 2017-06-30 Processes for preparing phosphorodiamidate morpholino oligomers Active AU2017270598B2 (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201662341049P 2016-05-24 2016-05-24
US201662340953P 2016-05-24 2016-05-24
US62/341,049 2016-05-24
US62/340,953 2016-05-24
US201662357134P 2016-06-30 2016-06-30
US201662357153P 2016-06-30 2016-06-30
US62/357,134 2016-06-30
US62/357,153 2016-06-30
US201762508256P 2017-05-18 2017-05-18
US62/508,256 2017-05-18
PCT/US2017/040311 WO2017205879A2 (fr) 2016-05-24 2017-06-30 Procédés de préparation d'oligomères morpholino de phosphorodiamidate

Publications (2)

Publication Number Publication Date
AU2017270598A1 AU2017270598A1 (en) 2019-01-17
AU2017270598B2 true AU2017270598B2 (en) 2022-12-01

Family

ID=64425889

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017270598A Active AU2017270598B2 (en) 2016-05-24 2017-06-30 Processes for preparing phosphorodiamidate morpholino oligomers

Country Status (10)

Country Link
EP (1) EP3463389A4 (fr)
JP (1) JP7022079B2 (fr)
KR (1) KR102523522B1 (fr)
CN (1) CN109152792B (fr)
AU (1) AU2017270598B2 (fr)
CA (1) CA3024153A1 (fr)
CO (1) CO2018013831A2 (fr)
MX (1) MX2018014160A (fr)
SG (1) SG11201809502YA (fr)
WO (1) WO2017205879A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI541024B (zh) 2010-09-01 2016-07-11 日本新藥股份有限公司 反義核酸
MA45183A (fr) 2016-05-24 2019-04-10 Sarepta Therapeutics Inc Procédés de préparation d'oligomères morpholino de phosphorodiamidate
CN109152775B (zh) * 2016-06-30 2022-04-26 萨勒普塔医疗公司 制备磷酸二酰胺吗啉代寡聚物的方法
EP4230196A1 (fr) 2022-02-21 2023-08-23 Som Innovation Biotech, S.A. Composés à utiliser dans le traitement des dystrophinopathies
KR20240105985A (ko) 2022-12-29 2024-07-08 최해용 스마트폰 용 프로젝터

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013082551A1 (fr) * 2011-11-30 2013-06-06 Sarepta Therapeutics, Inc. Inclusion d'exon induite pour l'amyotrophie spinale

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3022967B2 (ja) 1985-03-15 2000-03-21 アンチバイラルズ インコーポレイテッド 立体規則性ポリヌクレオチド結合ポリマー
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5521063A (en) 1985-03-15 1996-05-28 Antivirals Inc. Polynucleotide reagent containing chiral subunits and methods of use
US5217866A (en) 1985-03-15 1993-06-08 Anti-Gene Development Group Polynucleotide assay reagent and method
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US5166315A (en) 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
EP0433345B1 (fr) 1988-09-01 1994-04-20 Forskningscenter Riso Procede de synthese de peptides et support solide de realisation dudit procede
AU694157B2 (en) * 1993-12-29 1998-07-16 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine adenosine antagonists
US8067571B2 (en) 2005-07-13 2011-11-29 Avi Biopharma, Inc. Antibacterial antisense oligonucleotide and method
US8076476B2 (en) * 2007-11-15 2011-12-13 Avi Biopharma, Inc. Synthesis of morpholino oligomers using doubly protected guanine morpholino subunits
US8299206B2 (en) * 2007-11-15 2012-10-30 Avi Biopharma, Inc. Method of synthesis of morpholino oligomers
MX2010004955A (es) 2007-11-15 2010-06-30 Avi Biopharma Inc Metodo de sintesis de oligomeros de morfolina.
US9050373B2 (en) * 2010-05-13 2015-06-09 The Charlotte-Mecklenburg Hospital Authority Pharmaceutical compositions comprising antisense oligonucleotides and methods of using same
KR20200133284A (ko) * 2010-05-28 2020-11-26 사렙타 쎄러퓨틱스, 인코퍼레이티드 변형된 서브유니트간 결합 및/또는 말단 그룹을 갖는 올리고뉴클레오타이드 유사체
TWI541024B (zh) * 2010-09-01 2016-07-11 日本新藥股份有限公司 反義核酸
RS55610B1 (sr) 2010-09-30 2017-06-30 Nippon Shinyaku Co Ltd Derivat morfolino nukleinske kiseline
WO2012150960A1 (fr) * 2011-05-05 2012-11-08 Avi Biopharma, Inc. Conjugués peptides/oligonucléotides
RS58529B1 (sr) * 2013-03-14 2019-04-30 Sarepta Therapeutics Inc Sastavi koji preskaču egzon za tretiranje mišićne distrofije
NZ731587A (en) * 2013-03-14 2021-07-30 Sarepta Therapeutics Inc Exon skipping compositions for treating muscular dystrophy
WO2014189142A1 (fr) * 2013-05-24 2014-11-27 味の素株式会社 Procédé de fabrication de morpholino-oligonucléotide
TWI737736B (zh) * 2016-05-24 2021-09-01 美商薩羅塔治療公司 製備磷醯二胺嗎啉代寡聚物之方法
MA49775A (fr) * 2016-05-24 2020-06-10 Sarepta Therapeutics Inc Procédés de préparation d'oligomères morpholino de phosphorodiamidate
TW201811807A (zh) * 2016-06-30 2018-04-01 美商薩羅塔治療公司 用於肌肉萎縮症之外顯子跳躍寡聚物
CN109152775B (zh) * 2016-06-30 2022-04-26 萨勒普塔医疗公司 制备磷酸二酰胺吗啉代寡聚物的方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013082551A1 (fr) * 2011-11-30 2013-06-06 Sarepta Therapeutics, Inc. Inclusion d'exon induite pour l'amyotrophie spinale

Also Published As

Publication number Publication date
EP3463389A2 (fr) 2019-04-10
KR102523522B1 (ko) 2023-04-20
CO2018013831A2 (es) 2018-12-28
CA3024153A1 (fr) 2017-11-30
CN109152792A (zh) 2019-01-04
WO2017205879A2 (fr) 2017-11-30
JP7022079B2 (ja) 2022-02-17
EP3463389A4 (fr) 2020-02-19
AU2017270598A1 (en) 2019-01-17
WO2017205879A3 (fr) 2018-01-18
KR20190020674A (ko) 2019-03-04
SG11201809502YA (en) 2018-12-28
MX2018014160A (es) 2019-04-01
CN109152792B (zh) 2021-09-14
JP2019518748A (ja) 2019-07-04

Similar Documents

Publication Publication Date Title
AU2017271524B2 (en) Processes for preparing phosphorodiamidate morpholino oligomers
AU2017270975B2 (en) Processes for preparing phosphorodiamidate morpholino oligomers
US11384105B2 (en) Processes for preparing oligomers
AU2017270598B2 (en) Processes for preparing phosphorodiamidate morpholino oligomers
US20220112491A1 (en) Processes for preparing phosphorodiamidate morpholino oligomers
US11472824B2 (en) Processes for preparing phosphorodiamidate morpholino oligomers
CN109152775A (zh) 制备磷酸二酰胺吗啉代寡聚物的方法
HK40114872A (en) Process for preparing phosphorodiamidate morpholino oligomers
HK40007452A (en) Processes for preparing phosphorodiamidate morpholino oligomers
HK40007452B (en) Processes for preparing phosphorodiamidate morpholino oligomers
HK40005805A (en) Processes for preparing oligomers

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)